Cobas ampliprep/cobas TaqMan HIV-1 v2.0 assay: consequences at the cohort level.

<h4>Background</h4>High-sensitive real-time PCR assays are routinely used to monitor HIV-1 infected subjects. Inter-assay discrepancies have been described at the low viral load (VL) end, where clinical decisions regarding possible virological rebound are based.<h4>Methods</h4&g...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ninon Taylor, Katharina Grabmeier-Pfistershammer, Alexander Egle, Richard Greil, Armin Rieger, Bruno Ledergerber, Hannes Oberkofler
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/6cdea8d6db7e4636a09860c34a10b6af
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6cdea8d6db7e4636a09860c34a10b6af
record_format	dspace
spelling	oai:doaj.org-article:6cdea8d6db7e4636a09860c34a10b6af2021-11-18T08:57:31ZCobas ampliprep/cobas TaqMan HIV-1 v2.0 assay: consequences at the cohort level.1932-620310.1371/journal.pone.0074024https://doaj.org/article/6cdea8d6db7e4636a09860c34a10b6af2013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24023696/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>High-sensitive real-time PCR assays are routinely used to monitor HIV-1 infected subjects. Inter-assay discrepancies have been described at the low viral load (VL) end, where clinical decisions regarding possible virological rebound are based.<h4>Methods</h4>A retrospective study was performed to analyze frequencies of viral blips after transition to the COBAS Ampliprep/COBAS TaqMan v2.0 HIV-1 assay (Taqman v2.0) in patients with prior undetectable VLs as measured with the Roche Cobas Ampliprep Amplicor HIV-1 Monitor Test, v1.5 (Amplicor) and was evaluated in comparison to a group of patients monitored with the Abbott Real-time HIV-1 assay (Abbott RT) during the same period of time.<h4>Results</h4>85 of 373 patients with VLs below the limit of quantification with Amplicor had VLs >50 copies/mL after transition to the TaqMan v2.0 assay. Among these 74.1% had VLs ranging from 50-499 copies/mL, 22.9% had VLs >500 copies/mL. From 22 patients with initial Taqman v2.0 based VLs exceeding 500 copies/mL, 6 patients had VLs <20 copies/mL after novel VL measurement on a next visit. In our control group with VL quantification using the Abbott RT assay, only 1 patient became detectable and showed a VL of <40 copies/mL after new measurement.<h4>Conclusions</h4>Transition to the Taqman v2.0 assay was accompanied by an increase of quantifiable HIV-1 VLs in patients with long term viral suppression under antiretroviral therapy that might be attributed to technical shortcomings of the Taqman v2.0 assay. A high test variability at the low VL end but also beyond was observed, making meaningful clinical interpretation of viral blips derived from different assays difficult.Ninon TaylorKatharina Grabmeier-PfistershammerAlexander EgleRichard GreilArmin RiegerBruno LedergerberHannes OberkoflerPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 8, p e74024 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Ninon Taylor Katharina Grabmeier-Pfistershammer Alexander Egle Richard Greil Armin Rieger Bruno Ledergerber Hannes Oberkofler Cobas ampliprep/cobas TaqMan HIV-1 v2.0 assay: consequences at the cohort level.
description	<h4>Background</h4>High-sensitive real-time PCR assays are routinely used to monitor HIV-1 infected subjects. Inter-assay discrepancies have been described at the low viral load (VL) end, where clinical decisions regarding possible virological rebound are based.<h4>Methods</h4>A retrospective study was performed to analyze frequencies of viral blips after transition to the COBAS Ampliprep/COBAS TaqMan v2.0 HIV-1 assay (Taqman v2.0) in patients with prior undetectable VLs as measured with the Roche Cobas Ampliprep Amplicor HIV-1 Monitor Test, v1.5 (Amplicor) and was evaluated in comparison to a group of patients monitored with the Abbott Real-time HIV-1 assay (Abbott RT) during the same period of time.<h4>Results</h4>85 of 373 patients with VLs below the limit of quantification with Amplicor had VLs >50 copies/mL after transition to the TaqMan v2.0 assay. Among these 74.1% had VLs ranging from 50-499 copies/mL, 22.9% had VLs >500 copies/mL. From 22 patients with initial Taqman v2.0 based VLs exceeding 500 copies/mL, 6 patients had VLs <20 copies/mL after novel VL measurement on a next visit. In our control group with VL quantification using the Abbott RT assay, only 1 patient became detectable and showed a VL of <40 copies/mL after new measurement.<h4>Conclusions</h4>Transition to the Taqman v2.0 assay was accompanied by an increase of quantifiable HIV-1 VLs in patients with long term viral suppression under antiretroviral therapy that might be attributed to technical shortcomings of the Taqman v2.0 assay. A high test variability at the low VL end but also beyond was observed, making meaningful clinical interpretation of viral blips derived from different assays difficult.
format	article
author	Ninon Taylor Katharina Grabmeier-Pfistershammer Alexander Egle Richard Greil Armin Rieger Bruno Ledergerber Hannes Oberkofler
author_facet	Ninon Taylor Katharina Grabmeier-Pfistershammer Alexander Egle Richard Greil Armin Rieger Bruno Ledergerber Hannes Oberkofler
author_sort	Ninon Taylor
title	Cobas ampliprep/cobas TaqMan HIV-1 v2.0 assay: consequences at the cohort level.
title_short	Cobas ampliprep/cobas TaqMan HIV-1 v2.0 assay: consequences at the cohort level.
title_full	Cobas ampliprep/cobas TaqMan HIV-1 v2.0 assay: consequences at the cohort level.
title_fullStr	Cobas ampliprep/cobas TaqMan HIV-1 v2.0 assay: consequences at the cohort level.
title_full_unstemmed	Cobas ampliprep/cobas TaqMan HIV-1 v2.0 assay: consequences at the cohort level.
title_sort	cobas ampliprep/cobas taqman hiv-1 v2.0 assay: consequences at the cohort level.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/6cdea8d6db7e4636a09860c34a10b6af
work_keys_str_mv	AT ninontaylor cobasampliprepcobastaqmanhiv1v20assayconsequencesatthecohortlevel AT katharinagrabmeierpfistershammer cobasampliprepcobastaqmanhiv1v20assayconsequencesatthecohortlevel AT alexanderegle cobasampliprepcobastaqmanhiv1v20assayconsequencesatthecohortlevel AT richardgreil cobasampliprepcobastaqmanhiv1v20assayconsequencesatthecohortlevel AT arminrieger cobasampliprepcobastaqmanhiv1v20assayconsequencesatthecohortlevel AT brunoledergerber cobasampliprepcobastaqmanhiv1v20assayconsequencesatthecohortlevel AT hannesoberkofler cobasampliprepcobastaqmanhiv1v20assayconsequencesatthecohortlevel
_version_	1718421087529730048

Cobas ampliprep/cobas TaqMan HIV-1 v2.0 assay: consequences at the cohort level.

Ejemplares similares